Resonance Health

Business Overview

Team

About

Market Data

Home

Contact

Shareholder Documents

Shareholder Information

Why Invest

Announcements

Poppins

Resonance Health Investor Hub

 is a non-invasive MRI based solution for quantifying liver iron concentration across the full spectrum seen clinically and is an invaluable tool in the diagnosis and management of patients with all iron overload related conditions.

 assesses the iron loading in the myocardium. Cardiac T2* may be used on its own or as part of a dual analysis package along with FerriScan® to provide more comprehensive information regarding iron storage in different organs and proper clinical management of risks and treatment plan.

 gained FDA clearance in December 2013 for the evaluation of fatty liver. FerriScan® and HepaFat-Scan® are analysed in Resonance Health’s image analysis laboratory (Core Lab), which provides quality certified central image analysis services to the clinical community and to clinical trials. Accurate imaging end points are increasingly used in clinical trials, providing quantitative and direct evidence for regulatory submissions.

Since then, Resonance Health has broadened its portfolio with both Core Lab and AI powered products for optimal screening, diagnosis, and management of patients in a variety of clinical settings.

Resonance Health is a MedTech company listed on the Australian Securities Exchange (ASX:RHT). Resonance Health specialises in the development and commercialisation of non-invasive medical imaging analysis and clinical trial services. We provide innovative industry leading quantitative calculations and evaluations essential in the management of particular diseases, especially in relation to iron overload and hepatic steatosis.

Quick links